Piramal Pharma Solutions Introduces Payload-Linker Development & Manufacturing Suite

Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., has unveiled a new payload-linker development and manufacturing suite at its Riverview, Michigan drug substance facility.

This launch is part of the company’s broader $90 million investment plan to extend U.S.-based manufacturing capabilities, announced last year. These strategic enhancements reinforce PPS’s commitment to bringing complex and innovative therapies to patients quickly and reliably.

“The launch of our new payload-linker suite at Riverview marks a major milestone for PPS and our partners,” said Peter DeYoung, CEO, Piramal Global Pharma. “The suite places world-class expertise, advanced technology, and commercial-scale payload-linker capabilities right here in Michigan, empowering our customers to accelerate the development and delivery of life-changing therapies, like ADCs. This investment demonstrates our deep commitment to U.S.-based innovation and manufacturing, ensuring our partners benefit from unmatched efficiency, supply chain security, and a seamless path from concept to clinic for these critical medicines.”

The Riverview site provides a range of capabilities for APIs and HPAPIs. Leveraging its specialized HPAPI knowledge and abilities, it serves as PPS’s dedicated payload-linker supplier, making it critical to ADCelerate – PPS’s rapid, integrated approach to phase I ADC development.

The addition of this payload-linker suite is designed to help PPS accelerate partners’ timelines and adapt to evolving market needs. Equipped with advanced containment, automation, and analytical technologies, the suite enables seamless scaling of payload-linker programs. This further strengthens the ADCelerate platform and positions PPS to meet the rising demand for ADCs and other bioconjugate therapies.